Differences in the Composition of Gut Microbiota between Patients with Parkinson's Disease and Healthy Controls: A Cohort StudyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This prospective cohort study compared the composition of gastrointestinal microbiota between patients with Parkinson's disease (PD) treated only with Levodopa and healthy controls. Fecal samples were collected from all participants and analyzed using Next-Generation Sequencing to assess microbiota composition. The study's endpoint was the difference in gut microbiota composition between the two groups, motivated by the idea that the gut microbiome and colonic inflammation may be associated with PD predisposition and progression.
Who was studied?
The study enrolled 27 hospitalized PD patients with well-controlled symptoms, recruited at a single academic hospital between July 2019 and July 2020. The control group consisted of 44 healthy subjects matched for age. Demographic data and medical history were collected from all participants using a set of questionnaires.
What were the most important findings?
PD patients showed a higher abundance of the Bacteroides phylum, the class Corynebacteria within phylum Actinobacteria, and the class Deltaproteobacteria within phylum Proteobacteria. Genera more abundant in PD patients included Butyricimonas, Robinsoniella, and Flavonifractor. At the species level, Akkermansia muciniphila, Eubacterium biforme, and Parabacteroides merdae were identified as more common in the gut microbiota of PD patients compared with healthy controls.
What are the greatest implications of this study?
The findings indicate that patients with PD have a distinct gut microbiota composition compared to healthy, age-matched controls. This distinct microbial signature, spanning multiple phyla, classes, genera, and species, supports the broader hypothesis that gut microbiome alterations are linked to PD. These differences may serve as a basis for future research into the gut microbiome's role in PD predisposition and progression, though the abstract does not describe specific mechanistic or clinical applications.